StockNews.AI
NVS
StockNews.AI
54 days

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease

1. ProFound and Novartis collaborate to develop cardiovascular therapeutics. 2. The collaboration includes $25M upfront and up to $750M in milestones. 3. ProFound seeks to identify novel proteins for drug targets. 4. Novartis emphasizes commitment to innovative cardiovascular treatments. 5. The partnership aims to address the burden of cardiovascular disease.

5m saved
Insight
Article

FAQ

Why Bullish?

Novartis’s collaboration expands its pipeline in cardiovascular treatments, potentially boosting market confidence.

How important is it?

The collaboration strengthens Novartis's position in a lucrative therapeutic area, making it significant for investors.

Why Long Term?

Novel drug development can take years; significant impacts typically unfold over time.

Related Companies

PFEBMYMRK
June 26, 2025 06:30 ET  | Source: ProFound Therapeutics, Inc. ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target ProFound to leverage its ProFoundry™ Platform to mine the expanded proteome to identify previously unknown proteins as novel drug targets for cardiovascular disease CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProFound™ Therapeutics, a company pioneering the expanded human proteome to develop first-in-class medicines for multiple diseases, today announced a four-year collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease leveraging its ProFoundry™ Platform. This collaboration aims to bring innovative solutions to a growing population of patients by joining ProFound’s unique capabilities in the identification of novel proteins from the expanded proteome as drugs and drug targets with Novartis’ exceptional cardiovascular drug development expertise enabled by their longstanding commitment to helping people with cardiovascular diseases. The ProFoundry Platform combines multi-layered sources of biological data with advanced computational tools to uncover, investigate, and validate a rich source of proteins hidden within the expanded human proteome and elucidate novel protein drugs and drug targets from these findings. “We are thrilled to partner with Novartis, whose leadership in cardiovascular innovation is widely recognized across the industry,” said John Lepore, M.D., CEO of ProFound Therapeutics and Flagship Pioneering CEO-Partner. “This collaboration further validates the power of our ProFoundry Platform to go beyond traditional target discovery approaches by tapping into the vast, largely unexplored biology of the expanded human proteome. Together, we have the opportunity to accelerate the discovery of entirely new targets and support the development of transformative therapies to address the growing global burden of cardiovascular disease.” Fiona Marshall, Ph.D., President, Biomedical Research at Novartis, added “Novartis is committed to identifying novel therapeutic targets to drive the discovery and development of innovative medicines for patients with cardiovascular disease. We are excited to collaborate with ProFound and combine our respective expertise and capabilities to explore under-researched biology, uncover new mechanisms, and translate pioneering science into life-changing treatments.” Under the terms of the four-year collaboration agreement, ProFound will receive $25 million in upfront and near-term milestone payments with the potential transaction value from downstream milestones of $750 million per selected target, with additional potential for tiered royalties. About ProFound™ Therapeutics ProFound Therapeutics is discovering proteins hidden within the expanded human proteome to uncover novel protein drugs and drug targets, producing first-in-class medicines for a multitude of diseases. The company’s ProFoundry™ Platform uses state-of-the-art protein detection technologies to systematically identify and validate novel proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 by Flagship Pioneering. For more information, please visit www.profoundtx.com Media Contacts: press@flagshippioneering.com

Related News